Seagen

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about
Seagen, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Seagen please access Flcube.comFineline Info & Tech (Flcube.com) provides you with comprehensive information about Seagen, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare.

Novo Nordisk Opens Its Next Chapter With 'Lasting Health Starts Now' Rebrand and 'The Novo Way' Culture – Single 'Novo' Name Signals a Faster, Consumer‑Driven Era
Company

Novo Nordisk Opens Its Next Chapter With ‘Lasting Health Starts Now’ Rebrand and ‘The Novo Way’ Culture – Single ‘Novo’ Name Signals a Faster, Consumer‑Driven Era

Novo Nordisk (NYSE: NVO) today unveiled a corporate rebrand centred on "Lasting Health Starts Now" and the single "Novo" name, together with an updated corporate culture, "The Novo Way", designed…

Sichuan Biokin's HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Sichuan Biokin’s HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Henlius' Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China's Bone Health Market

Henlius’ Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China’s Bone Health Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer
CompanyDrug

Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer

Genmab's Tivdak Approved in Japan for Advanced Cervical Cancer Treatment
CompanyDrug

Genmab’s Tivdak Approved in Japan for Advanced Cervical Cancer Treatment

Zai Lab Submits TIVDAK BLA to China's NMPA for Cervical Cancer Treatment
CompanyDrug

Zai Lab Submits TIVDAK BLA to China’s NMPA for Cervical Cancer Treatment

GSK's Blenrep and Star Pharma's Topiramate Solution Target Priority Review in China
CompanyDrug

GSK’s Blenrep and Star Pharma’s Topiramate Solution Target Priority Review in China

CompanyDeals

Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC

CompanyDeals

Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics

Company

Pfizer’s $43 Billion Seagen Acquisition Closes Amid Lackluster 2024 Forecast

CompanyDrug

Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study

Show More